Latest research on Linezolid

Linezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA). The drug works by inhibiting the initiation of bacterial protein synthesis.

Linezolid side effects

Among group 5 drugs, Linezolid may be the first option because a recent metaanalysis showed that only Linezolid was independently associated with favorable outcomes in the treatment of XDR-TB or fluoroquinolone-resistant MDR-TB20. [source, 2016]
From these 223, 21 were excluded because of major modifications of the standard treatment protocol, such as addition of Linezolid, and 5 because of initial Kanamycin resistance. [source, 2016]
Only the patients receiving empirical Linezolid showed borderline statistical significance towards increased mortality (p = 0.05; RR = 2.4) (Table 4). [source, 2016]
SS is caused due to excessive serotonergic activity; and in this case, it seems likely that it was caused due to concurrent administration of drugs that increased serotonergic activity (fluoxetine, Sertraline, Fluvoxamine, Linezolid, and Fentanyl), rather than any single drug alone. [source, 2016]
Currently indicated for the treatment of complicated and uncomplicated skin and skin structure infections (cSSSI), community-acquired and nosocomial pneumonia, as well as infections caused by VRE, Linezolid has found widespread utilization in clinical practice [10]. [source, 2015]
Organisms with decreased susceptibility to Linezolid also commonly have elevated tedizolid MIC. [source, 2015]
In staphylococci and enterococci, modifications to L4 in particular appear to have a clinically significant impact on Linezolid MIC, leading to a fourfold increase when added to previously susceptible isolates [27]. [source, 2015]
As such, Linezolid MIC have been observed to increase two- to fourfold in organisms acquiring the cfr gene [29]. [source, 2015]
In vitro data, however, showed a significantly lower MPS 50% inhibitory concentration (IC50) for tedizolid compared to that of Linezolid (0.3 versus 6 µM respectively), suggesting increased risk of neurotoxicity. [source, 2015]
The FDA issued a warning on the label of Linezolid to caution clinicians of this possible effect if given concurrently with other agents that increase serotonin including selective serotonin reuptake inhibitors and serotonin–norepinephrine reuptake inhibitors. [source, 2015]